Anete Trajman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4311190/publications.pdf

Version: 2024-02-01

84 papers	3,398 citations	270111 25 h-index	175968 55 g-index
95 all docs	95 docs citations	95 times ranked	5947 citing authors

#	Article	IF	Citations
1	Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a cost-effectiveness and budget impact analysis. The Lancet Regional Health Americas, 2022, 8, 100166.	1.5	5
2	Contribution of primary care expansion to Sustainable Development Goal 3 for health: a microsimulation of the 15 largest cities in Brazil. BMJ Open, 2022, 12, e049251.	0.8	1
3	High-dose rifamycins in the treatment of TB: a systematic review and meta-analysis. Thorax, 2022, 77, 1210-1218.	2.7	4
4	Child Contact Case Managementâ€"A Major Policy-Practice Gap in High-Burden Countries. Pathogens, 2022, 11, 1.	1.2	17
5	Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clinical Infectious Diseases, 2022, 75, 2201-2210.	2.9	5
6	Perfil sociodemogrÃ¡fico e de saÃºde de solicitantes de refÃºgio no Rio de Janeiro, 2016â€"2017. Revista De Saude Publica, 2022, 56, 31.	0.7	2
7	Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. PLoS Medicine, 2022, 19, e1004032.	3.9	6
8	Classification and regression trees for predicting the risk of a negative test result for tuberculosis infection in Brazilian healthcare workers: a cross-sectional study. Revista Brasileira De Epidemiologia, 2021, 24, e210035.	0.3	0
9	Effects of programmatic interventions to improve the management of latent tuberculosis: a follow up study up to five months after implementation. BMC Public Health, 2021, 21, 177.	1.2	2
10	A simple protocol for tuberculin skin test reading certification. Cadernos De Saude Publica, 2021, 37, e00027321.	0.4	1
11	Implementing tuberculosis preventive treatment in high-prevalence settings. International Journal of Infectious Diseases, 2021, 113, S13-S15.	1.5	5
12	Improving diagnosis of tuberculosis in children. Lancet Infectious Diseases, The, 2021, 21, 302-303.	4.6	6
13	Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health, The, 2021, 6, e272-e282.	4.7	18
14	Record linkage under suboptimal conditions for data-intensive evaluation of primary care in Rio de Janeiro, Brazil. BMC Medical Informatics and Decision Making, 2021, 21, 190.	1.5	6
15	Racial and socioeconomic disparities in multimorbidity and associated healthcare utilisation and outcomes in Brazil: a cross-sectional analysis of three million individuals. BMC Public Health, 2021, 21, 1287.	1.2	21
16	Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infectious Diseases, The, 2020, 20, 318-329.	4.6	37
17	Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings. Annals of Internal Medicine, 2020, 173, 169-178.	2.0	20
18	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2020, 73, e3545-e3554.	2.9	19

#	Article	IF	Citations
19	Cost-effectiveness of newer technologies for the diagnosis of Mycobacterium tuberculosis infection in Brazilian people living with HIV. Scientific Reports, 2020, 10, 21823.	1.6	9
20	Active and latent tuberculosis in refugees and asylum seekers: a systematic review and meta-analysis. BMC Public Health, 2020, 20, 838.	1.2	30
21	Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ, The, 2020, 370, m2516.	3.0	673
22	Primary healthcare expansion and mortality in Brazilâ€™s urban poor: A cohort analysis of 1.2 million adults. PLoS Medicine, 2020, 17, e1003357.	3.9	32
23	A summary of the proceedings of a meeting on the treatment of latent tuberculosis infection in target populations in Brazil. Jornal Brasileiro De Pneumologia, 2020, 46, e20200023-e20200023.	0.4	1
24	Knowledge, attitudes and practices on tuberculosis transmission and prevention among auxiliary healthcare professionals in three Brazilian high-burden cities: a cross-sectional survey. BMC Health Services Research, 2019, 19, 532.	0.9	14
25	Prevalence of sexual violence among refugees: a systematic review. Revista De Saude Publica, 2019, 53, 78.	0.7	39
26	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	2.9	53
27	Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial. BMJ Open, 2019, 9, e025831.	0.8	18
28	DoenÃ§as raras: quem paga qual conta?. Cadernos De Saude Publica, 2019, 35, e00145719.	0.4	1
29	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	5.2	80
30	The impact of the Brazilian Family Health Strategy and the conditional cash transfer on tuberculosis treatment outcomes in Rio de Janeiro: an individual-level analysis of secondary data. Journal of Public Health, 2018, 40, e359-e366.	1.0	20
31	Rastreamento populacional para o cÃ¢ncer de prÃ³stata: mais riscos que benefÃcios. Physis, 2018, 28, .	0.1	4
32	Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial. BioMed Research International, 2018, 2018, 1-11.	0.9	1
33	ItinerÃ¡rio terapÃªutico de doentes com tuberculose vivendo em situaÃ§Ã£o de rua no Rio de Janeiro. Physis, 2018, 28, .	0.1	6
34	Tuberculosis among correctional facility workers: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0207400.	1.1	12
35	New short regimens for latent tuberculosis treatment: safety first!. European Respiratory Journal, 2018, 52, 1802180.	3.1	5
36	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	6.3	452

#	Article	IF	Citations
37	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. New England Journal of Medicine, 2018, 379, 440-453.	13.9	267
38	Safety and Side Effects of Rifampin versus Isoniazid in Children. New England Journal of Medicine, 2018, 379, 454-463.	13.9	124
39	Second month sputum smear as a predictor of tuberculosis treatment outcomes in Brazil. BMC Research Notes, 2018, 11, 414.	0.6	8
40	Tuberculosis infection among cocaine crack users in Brazil. International Journal of Drug Policy, 2018, 59, 24-27.	1.6	3
41	Os Objetivos do Desenvolvimento SustentÃ¡vel e a tuberculose no Brasil: desafios e potencialidades. Cadernos De Saude Publica, 2018, 34, e00030318.	0.4	14
42	Knowledge and perceptions of tuberculosis transmission and prevention among physicians and nurses in three Brazilian capitals with high incidence of tuberculosis. Jornal Brasileiro De Pneumologia, 2018, 44, 168-170.	0.4	7
43	It takes more than a sensitive test to find more tuberculosis cases. Lancet Infectious Diseases, The, 2017, 17, 357-358.	4.6	1
44	Frequency of indeterminate results from an interferon-gamma release assay among HIV-infected individuals. Jornal Brasileiro De Pneumologia, 2017, 43, 215-218.	0.4	5
45	Knowledge about tuberculosis transmission and prevention and perceptions of health service utilization among index cases and contacts in Brazil: Understanding losses in the latent tuberculosis cascade of care. PLoS ONE, 2017, 12, e0184061.	1.1	19
46	Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infectious Diseases, 2017, 17, 718.	1.3	30
47	The impact of the Brazilian family health on selected primary care sensitive conditions: A systematic review. PLoS ONE, 2017, 12, e0182336.	1.1	76
48	Active tuberculosis case findingâ€"do we have the right tool?. Lancet Infectious Diseases, The, 2016, 16, 986-987.	4.6	2
49	Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services. BMC Health Services Research, 2015, 16, 27.	0.9	8
50	Cost analysis of nucleic acid amplification for diagnosing pulmonary tuberculosis, within the context of the Brazilian Unified Health Care System. Jornal Brasileiro De Pneumologia, 2015, 41, 536-538.	0.4	16
51	Impact on Patientsâ€™ Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial. PLoS ONE, 2015, 10, e0123252.	1.1	40
52	The adoption of a new diagnostic technology for tuberculosis in two Brazilian cities from the perspective of patients and healthcare workers: a qualitative study. BMC Health Services Research, 2015, 15, 275.	0.9	7
53	Effectiveness of RHZE-FDC (fixed-dose combination) compared to RH-FDCâ€‰+â€‰Z for tuberculosis treatment in Brazil: a cohort study. BMC Infectious Diseases, 2015, 15, 81.	1.3	7
54	Operational lessons drawn from pilot implementation of Xpert MTB/Rif in Brazil. Bulletin of the World Health Organization, 2014, 92, 613-617.	1.5	13

#	Article	IF	Citations
55	Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial. PLoS Medicine, 2014, 11, e1001766.	3.9	107
56	High positive predictive value of Xpert in a low rifampicin resistance prevalence setting. European Respiratory Journal, 2014, 44, 1711-1713.	3.1	11
57	Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS. BioMed Research International, 2014, 2014, 1-7.	0.9	8
58	Accuracy of polimerase chain reaction for the diagnosis of pleural tuberculosis. Respiratory Medicine, 2014, 108, 918-923.	1.3	28
59	Tuberculosis Infection Control: Potential Benefit of a New Rapid Tuberculosis Test in a Human Immunodeficiency Virus/AIDS Reference Hospital. Infection Control and Hospital Epidemiology, 2014, 35, 1206-1207.	1.0	1
60	Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in brazil: an ecological study. BMC Public Health, 2013, 13, 321.	1.2	0
61	Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges. BMC Public Health, 2013, 13, 279.	1.2	4
62	Pulmonary Tuberculosis. Pulmonary Medicine, 2013, 2013, 1-1.	0.5	1
63	How Methodologic Differences Affect Results of Economic Analyses: A Systematic Review of Interferon Gamma Release Assays for the Diagnosis of LTBI. PLoS ONE, 2013, 8, e56044.	1.1	23
64	Cost-Effectiveness of QuantiferonÂ®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil. PLoS ONE, 2013, 8, e59546.	1.1	43
65	Preditores dos desfechos do tratamento da tuberculose. Jornal Brasileiro De Pneumologia, 2012, 38, 88-97.	0.4	34
66	GargalosÃ§Ãµes para a incorporaÃ§Ã£o de novas tecnologias na rede pÃºblica laboratorial de tuberculose no Brasil. Jornal Brasileiro De Pneumologia, 2012, 38, 766-770.	0.4	8
67	O papel das ligas acadÃªmicas na formaÃ§Ã£o profissional. Jornal Brasileiro De Pneumologia, 2012, 38, 803-805.	0.4	9
68	Fatores associados ao atraso no diagnÃ³stico da tuberculose pulmonar no estado do Rio de Janeiro. Jornal Brasileiro De Pneumologia, 2011, 37, 512-520.	0.4	50
69	Occupational respiratory infections. Current Opinion in Pulmonary Medicine, 2010, 16, 1.	1.2	11
70	Proposta de vigilÃ¢ncia de Ã³bitos por tuberculose em sistemas de informaÃ§Ã£o. Revista De Saude Publica, 2010, 44, 1072-1078.	0.7	19
71	Tuberculose e gÃªnero em um municÃpio prioritÃ¡rio no estado do Rio de Janeiro. Jornal Brasileiro De Pneumologia, 2010, 36, 621-625.	0.4	32
72	Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax, 2010, 65, 582-587.	2.7	47

#	Article	IF	Citations
73	Assessment of the IgA Immunoassay Diagnostic Potential of the Mycobacterium tuberculosis MT10.3-MPT64 Fusion Protein in Tuberculous Pleural Fluid. Vaccine Journal, 2010, 17, 1963-1969.	3.2	13
74	Patients' Costs and Cost-Effectiveness of Tuberculosis Treatment in DOTS and Non-DOTS Facilities in Rio de Janeiro, Brazil. PLoS ONE, 2010, 5, e14014.	1.1	70
75	Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment. International Journal of Tuberculosis and Lung Disease, 2010, 14, 551-9.	0.6	27
76	McNemar Ï‡²test revisited: comparing sensitivity and specificity of diagnostic examinations. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 77-80.	0.6	187
77	Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection. Annals of Internal Medicine, 2008, 149, 689.	2.0	180
78	Knowledge and practices of medical students to prevent tuberculosis transmission in Rio de Janeiro, Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 24, 265-270.	0.6	16
79	Pleural fluid ADA, IgAâ€ELISA and PCR sensitivities for the diagnosis of pleural tuberculosis. Scandinavian Journal of Clinical and Laboratory Investigation, 2007, 67, 877-884.	0.6	33
80	Choosing incentives to stimulate tuberculosis treatment compliance in a poor county in Rio de Janeiro state, Brazil. Medical Science Monitor, 2006, 12, PH1-5.	0.5	6
81	Third-party informed consent in research with adolescents: The good, the bad and the ugly. Social Science and Medicine, 2005, 61, 985-988.	1.8	14
82	Diagnosing Pleural Tuberculosis. Chest, 2004, 125, 2366.	0.4	6
83	Ã“bitos atribuÃdos Ã tuberculose no Estado do Rio de Janeiro. Jornal Brasileiro De Pneumologia, 2004, 30, 417-423.	0.4	32
84	Knowledge about STD/AIDS and sexual behavior among high school students in Rio de Janeiro, Brazil. Cadernos De Saude Publica, 2003, 19, 127-133.	0.4	27